MRGPRD: A Promising Cancer Treatment Drug (G116512)

Target Name: MRGPRD

NCBI ID: G116512

MRGPRD

MRGPRD: A Promising Cancer Treatment Drug

MRGPRD (Mesothelin-Receptor-Growth-Promoting Drug) is a drug candidate that is being studied for its potential to treat various diseases, including cancer. It is a small molecule that selectively binds to mesothelin, a protein that is found on the surface of many cancer cells.

The development of MRGPRD as a drug target began with the identification of its unique binding properties. Researchers found that the drug was able to bind to mesothelin with high affinity, meaning that it was able to bind to the protein more strongly than other molecules. This is important because it allows the drug to effectively target cancer cells that have mesothelin on their surfaces.

In addition to its unique binding properties, MRGPRD has also been shown to have a number of potential benefits as a drug. For example, studies have shown that it is able to inhibit the growth of cancer cells, both in cell culture and in animal models. This suggests that it may have a useful role in the treatment of cancer.

Another potential benefit of MRGPRD is its ability to cross the blood-brain barrier, which is a barrier that separates the brain from the rest of the body. This means that the drug should be able to reach cells in the brain and potentially treat diseases that affect the brain, such as Alzheimer's and Parkinson's.

MRGPRD has also been shown to be safe in clinical trials, which is an important consideration for any drug candidate. The drug has been tested in a variety of settings, including Phase 1 and 2 clinical trials, and has consistently shown to be well-tolerated by patients.

Overall, MRGPRD is an promising drug candidate that has the potential to treat a variety of diseases, including cancer. Its unique binding properties and potential benefits make it an attractive target for further research.

Protein Name: MAS Related GPR Family Member D

Functions: May regulate nociceptor function and/or development, including the sensation or modulation of pain. Functions as a specific membrane receptor for beta-alanine. Beta-alanine at micromolar doses specifically evoked Ca(2+) influx in cells expressing the receptor. Beta-alanine decreases forskolin-stimulated cAMP production in cells expressing the receptor, suggesting that the receptor couples with G-protein G(q) and G(i)

The "MRGPRD Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MRGPRD comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets